Current and Future Advances Driving the Strongest Growth Area in the Pharmaceutical Industry
De som köpt den här boken har ofta också köpt The Anxious Generation av Jonathan Haidt (inbunden).
Köp båda 2 för 3238 kr"An excellent balance between readability and depth of material.... The book is well referenced and provides plentiful opportunities to continue subject-specific learing." --mAbs Journal"An excellent book describing many aspects of therapeutic antibody generation and the current market share of these drugs. It is an up-to-date evaluation of their production and clinical utility." --Doody's Reviews
Dr William R. Strohl is Vice President of Biologics Research at Janssen R&D Biotechnology Center of Excellence, and was previously a leader in Merck's efforts to discover therapeutic monoclonal antibodies, as well as in-licensing of therapeutic targets and technologies associated with monoclonal antibodies. He has over 100 publications and several patents to his credit, and has edited two books.
Introduction to biologics and monoclonal antibodies; Value proposition for therapeutic monoclonal antibodies and Fc fusion proteins; Antibody structure - function relationships; Fundamental technologies for antibody engineering; Sources of antibody variable chains; Variable chain engineering - humanization and optimization approaches; Antibody interactions with the immune system; Monoclonal antibody targets and mechanisms of action; Therapeutic antibody classes; Antibody Fc engineering for optimal antibody performance; IgG glycans and glyco-engineering; Antibody fragments as therapeutics; Multiple antibody and multi-specificity approaches; FcFPs and similar constructs using Fc; Antibody-drug conjugates; Development issues: antibody stability, developability, immunogenicity, and comparability; Interactions of human IgGs with non-human systems; Cell line development; Issues facing therapeutic monoclonal antibodies for the future.